Rating Change
Citigroup analysts upgraded Texas Capital Bancshares, Inc. (NASDAQ:TCBIO) from Sell to Neutral on June 30, 2026.
Rating Change Citigroup analysts upgraded Texas Capital Bancshares, Inc. (NASDAQ:TCBIO) from Sell to Neutral on June 30, 2026. Market Context Texas Capital Bancshares, Inc.

Citigroup analysts upgraded Texas Capital Bancshares, Inc. (NASDAQ:TCBIO) from Sell to Neutral on June 30, 2026.
Texas Capital Bancshares, Inc. operates in the Financial Services sector. The stock currently trades at $20.40 with a market capitalization of $938.9M.
Analyst upgrades often act as catalysts for near-term price movement, particularly when they come from major firms with significant institutional following. Citigroup's upgrade suggests their analysts see improving fundamentals, a more favorable risk-reward profile, or upcoming catalysts that could drive the stock higher.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 1 Buy, 6 Hold, 3 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jun 30, 2026 | Citigroup | Neutral | N/A |
| Apr 28, 2026 | Citigroup | Sell | N/A |
| Apr 24, 2026 | RBC Capital | Sector Perform | N/A |
| Apr 24, 2026 | Piper Sandler | Neutral | N/A |
| Apr 01, 2026 | JP Morgan | Underweight | N/A |
Related Tools: Analyst Ratings Dashboard | View TCBIO Stock Page
A Neutral rating from Citigroup reflects the analyst's outlook on Texas Capital Bancshares, Inc. (NASDAQ:TCBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the TCBIO forecast page.
Current market data
NASDAQ · TCBIO
$20.55
Up: +$0.02 · +0.10%
Live quote updated
Keep reading